Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of erdafitinib versus chemotherapy or pembrolizumab in FGFR-altered advanced urothelial cancer
NL-OMON55515Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of erdafitinib in transitional cell carcinoma (TCC) and bladder cancer (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall survival. Started Nov 2019; status: active, not recruiting.
02
Drugs
erdafitinib
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON55515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55515.